Lund Bjarte Aarmo, Christopeit Tony, Guttormsen Yngve, Bayer Annette, Leiros Hanna-Kirsti S
The Norwegian Structural Biology Centre (NorStruct), Department of Chemistry, UiT The Arctic University of Norway , 9037 Tromsø, Norway.
Department of Chemistry, UiT The Arctic University of Norway , 9037 Tromsø, Norway.
J Med Chem. 2016 Jun 9;59(11):5542-54. doi: 10.1021/acs.jmedchem.6b00660. Epub 2016 May 20.
The spread of antibiotic resistant bacteria is a global threat that shakes the foundations of modern healthcare. β-Lactamases are enzymes that confer resistance to β-lactam antibiotics in bacteria, and there is a critical need for new inhibitors of these enzymes for combination therapy together with an antibiotic. With this in mind, we have screened a library of 490 fragments to identify starting points for the development of new inhibitors of the class D β-lactamase oxacillinase-48 (OXA-48) through surface plasmon resonance (SPR), dose-rate inhibition assays, and X-ray crystallography. Furthermore, we have uncovered structure-activity relationships and used alternate conformations from a crystallographic structure to grow a fragment into a more potent compound with a KD of 50 μM and an IC50 of 18 μM.
抗生素耐药菌的传播是一个全球性威胁,动摇了现代医疗保健的根基。β-内酰胺酶是使细菌对β-内酰胺抗生素产生耐药性的酶,迫切需要这些酶的新型抑制剂,以便与抗生素联合用于治疗。考虑到这一点,我们通过表面等离子体共振(SPR)、剂量率抑制试验和X射线晶体学,筛选了一个包含490个片段的文库,以确定开发D类β-内酰胺酶奥沙西林酶-48(OXA-48)新型抑制剂的起始点。此外,我们还揭示了构效关系,并利用晶体结构中的替代构象将一个片段扩展为一种更有效的化合物,其解离常数(KD)为50 μM,半数抑制浓度(IC50)为18 μM。